A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis

Completed

Plain-English translation of NCT02883452 on ClinicalTrials.gov ↗ · Source last updated June 2020 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Trial locations(1 site)

South Korea

Yeungnam University Hospital, Daegu